Viridian Therapeutics, Inc.\DE
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
- VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after subcutaneous dosing in healthy…